Drug FDA Class II Terminated Failed specifications
Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03
Lupin Pharmaceuticals Inc. Published Jun 26, 2024
Risk level
Class IIMay cause a temporary or reversible health problem; slight chance of serious harm.
Severity score 55/100
What should you do?
- Check whether you have this product, using the lot codes, UPCs, and dates listed below.
- Do not eat, serve, or sell the affected product.
- Return it to the place of purchase for a refund, or throw it away in a sealed bag so people and animals can’t get to it.
- Contact Lupin Pharmaceuticals Inc. or your place of purchase with questions, and see the source record below for full details.
Reason for recall
Failed Content Uniformity Specifications
Hazards
Failed Content Uniformity · primary
Affected products (1)
Cefixime for Oral Suspension USP 200 mg/5 mL (50 mL Pack size), Powder for oral suspension, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore Maryland, Manufactured by: Lupin Limited, Mandideep, India NDC 68180-407-03
CEFIXIME · 3,552 bottles
NDC: 68180-405, 68180-407, 68180-416, 68180-423, 68180-405-01, 68180-407-03, 68180-407-04, 68180-416-08, 68180-416-11, 68180-423-11, 68180-423-08
Lot codes: F201519
Code info: Lot F201519, Expiry: November 2024
Affected areas
Nationwide
Timeline
- InitiatedMay 30, 2024
- PublishedJun 26, 2024
- TerminatedApr 29, 2025
- Recall number
- D-0559-2024
- Agency
- U.S. Food and Drug Administration
- Country
- US
FDA records come from the openFDA drug enforcement-report dataset — the agency's full weekly enforcement list. Most entries are not issued as consumer press releases, so they won't appear on fda.gov/recalls or in a web search. The source record link above resolves this exact recall by its number.